A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of ASP3291 Following a Single Oral Dose in Subjects With Mild to Moderately Active Ulcerative Colitis.
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2012
At a glance
- Drugs ASP 3291 (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- 24 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Aug 2011 Actual end date Aug 2011 added as reported by ClinicalTrials.gov.
- 26 Mar 2011 New trial record